Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 23,568
  • Shares Outstanding, K 1,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,312 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 3.28
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.71

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.88 +26.62%
on 11/20/25
18.00 -30.50%
on 12/03/25
+2.41 (+23.86%)
since 11/19/25
3-Month
9.88 +26.62%
on 11/20/25
20.40 -38.68%
on 10/21/25
-0.20 (-1.57%)
since 09/19/25
52-Week
8.40 +48.93%
on 08/06/25
139.50 -91.03%
on 01/03/25
-114.99 (-90.19%)
since 12/19/24

Most Recent Stories

More News
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell presents positive clinical data in three posters at the San Antonio Breast Cancer Symposium (SABCS ® ) Phase 3 study of Bria-IMT™ plus immune check point inhibitor (CPI) continues to...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Over 230 patients screened and over 160 patients enrolled in BriaCell’s pivotal Phase 3 study in metastatic breast cancer (MBC) Enrollment exceeding expectations with strong clinical site and patient...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (SABCS), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Collaboration uses Receptor AI's platform to design highly selective anti-cancer kinase inhibitor products for BriaPro, a BriaCell subsidiary Partnership expected to expand BriaPro's small-molecule...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
Stocks in play: BriaCell Therapeutics Corp.

Will be presenting three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer ...

BCT.TO : 12.51 (unch)
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Three BriaCell poster presentations include updated key biomarker data from BriaCell’s pivotal Phase 3 study and updated survival data from the Phase 2 study of Bria-IMT™ plus immune check point inhibitor...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)
BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

SITC poster to be presented on Friday, November 7, 2025, emphasizes robust anti-cancer activity of next generation Bria-OTS+ platform Lead candidates Bria-BRES+™ (breast cancer) and Bria-PROS+™...

BCT.TO : 12.51 (unch)
BCTXW : 0.0439 (unch)
BCTXZ : 0.3900 (+14.71%)
BCTX : 8.95 (-0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes...

See More

Key Turning Points

3rd Resistance Point 12.91
2nd Resistance Point 12.82
1st Resistance Point 12.67
Last Price 12.51
1st Support Level 12.43
2nd Support Level 12.34
3rd Support Level 12.19

See More

52-Week High 139.50
Fibonacci 61.8% 89.42
Fibonacci 50% 73.95
Fibonacci 38.2% 58.48
Last Price 12.51
52-Week Low 8.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar